Det går fremad slut 2009 primo 2010
http://atlanta.bizjournals.com/atlanta/stories/2009/07/13/daily99.html?ana=yfcpc
Det er vel lige efter planen ?
http://atlanta.bizjournals.com/atlanta/stories/2009/07/13/daily99.html?ana=yfcpc
Det er vel lige efter planen ?
10/8 2009 17:28 1970 0
16547 Så blev vores kære aktie nævnt som en af 5 winning stocks 
http://www.fool.com/investing/mutual-funds/2009/08/07/do-you-own-these-5-winning-stocks.aspx
http://www.fool.com/investing/mutual-funds/2009/08/07/do-you-own-these-5-winning-stocks.aspx
11/8 2009 00:31 Hya 016559 Dendreon Signs Lease for New Manufacturing Facility In Atlanta
-- New Manufacturing Facility Under Development to Provide Additional Manufacturing Capacity to Support Commercialization of PROVENGE --
-- Ribbon-Cutting Ceremony Scheduled for September 30 --
SEATTLE and ATLANTA, Aug. 10, 2009 - Dendreon Corporation (Nasdaq: DNDN) today announced it has signed a lease agreement with Majestic Realty Co. to build a 160,000 square-foot manufacturing facility in Union City, Ga., where it expects to manufacture PROVENGE® (sipuleucel-T) for patients with advanced prostate cancer. The state of Georgia will be hosting a ribbon-cutting ceremony on September 30.
If approved by the U.S. Food and Drug Administration (FDA), Dendreon would launch PROVENGE from its existing facility in Morris Plains, N.J. and would then ramp up additional manufacturing capacity of PROVENGE at its other facilities under development in Union City and Seal Beach, Calif. once they are completed. The Company expects to disclose more details relating to its manufacturing facilities at an upcoming analyst day in New York City.
"We are pleased to announce that we are expanding our manufacturing capacity with the addition of two new facilities in Atlanta and Los Angeles," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We have particularly enjoyed partnering with the state of Georgia, Fulton County officials and the local community during this process and are grateful for their partnership and support as we prepare to commercialize PROVENGE to help the many patients with advanced prostate cancer who currently have few appealing treatment options."
"Hosting the 2009 BIO International Convention in May introduced biotechnology companies like Dendreon to Georgia's business assets," said Sonny Perdue, Governor of the State of Georgia. "Our state's world-class healthcare institutions and hospitals enable companies like Dendreon to conduct clinical research and engage in product development while benefiting from the vast scientific resources that Georgia has to offer."
About PROVENGE
PROVENGE is Dendreon's investigational product candidate for men with advanced prostate cancer and may represent the first in a new class of active cellular immunotherapies (ACIs) specifically designed to engage the patient's own immune system against cancer. PROVENGE and other ACIs are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. Dendreon recently announced that the pivotal Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study of PROVENGE in men with advanced prostate cancer met its primary endpoint of improving overall survival compared to a placebo control. The Company expects to complete its Biologics License Application (BLA) with the FDA in the fourth quarter of 2009.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.
Forward Looking Statements
This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including progress on the commercialization efforts for PROVENGE and requisite receipt of FDA licensure for marketing and the risk that additional capital could be needed in the future for the potential commercialization of PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.
Contact Information:
Investor Relations:
Jennifer Cook Williams
Dendreon Corporation
(206) 829-1500
Media:
Katherine Stueland
WeissComm Partners
(415) 946-1082
-- New Manufacturing Facility Under Development to Provide Additional Manufacturing Capacity to Support Commercialization of PROVENGE --
-- Ribbon-Cutting Ceremony Scheduled for September 30 --
SEATTLE and ATLANTA, Aug. 10, 2009 - Dendreon Corporation (Nasdaq: DNDN) today announced it has signed a lease agreement with Majestic Realty Co. to build a 160,000 square-foot manufacturing facility in Union City, Ga., where it expects to manufacture PROVENGE® (sipuleucel-T) for patients with advanced prostate cancer. The state of Georgia will be hosting a ribbon-cutting ceremony on September 30.
If approved by the U.S. Food and Drug Administration (FDA), Dendreon would launch PROVENGE from its existing facility in Morris Plains, N.J. and would then ramp up additional manufacturing capacity of PROVENGE at its other facilities under development in Union City and Seal Beach, Calif. once they are completed. The Company expects to disclose more details relating to its manufacturing facilities at an upcoming analyst day in New York City.
"We are pleased to announce that we are expanding our manufacturing capacity with the addition of two new facilities in Atlanta and Los Angeles," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We have particularly enjoyed partnering with the state of Georgia, Fulton County officials and the local community during this process and are grateful for their partnership and support as we prepare to commercialize PROVENGE to help the many patients with advanced prostate cancer who currently have few appealing treatment options."
"Hosting the 2009 BIO International Convention in May introduced biotechnology companies like Dendreon to Georgia's business assets," said Sonny Perdue, Governor of the State of Georgia. "Our state's world-class healthcare institutions and hospitals enable companies like Dendreon to conduct clinical research and engage in product development while benefiting from the vast scientific resources that Georgia has to offer."
About PROVENGE
PROVENGE is Dendreon's investigational product candidate for men with advanced prostate cancer and may represent the first in a new class of active cellular immunotherapies (ACIs) specifically designed to engage the patient's own immune system against cancer. PROVENGE and other ACIs are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. Dendreon recently announced that the pivotal Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study of PROVENGE in men with advanced prostate cancer met its primary endpoint of improving overall survival compared to a placebo control. The Company expects to complete its Biologics License Application (BLA) with the FDA in the fourth quarter of 2009.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.
Forward Looking Statements
This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including progress on the commercialization efforts for PROVENGE and requisite receipt of FDA licensure for marketing and the risk that additional capital could be needed in the future for the potential commercialization of PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.
Contact Information:
Investor Relations:
Jennifer Cook Williams
Dendreon Corporation
(206) 829-1500
Media:
Katherine Stueland
WeissComm Partners
(415) 946-1082
14/8 2009 16:04 1970 016795 og endnu et link:
http://www.thestreet.com/story/10575223/3/dendreon-vion-and-allos-biotech-mailbag.html
Ben L. writes, "I don't know if you listened to the recent Dendreon(DNDN Quote) quarterly conference call, but what was shared has obviously caused some concern amongst the investment community. The stock has been dropping since the call even though I have not seen any analyst downgrades for Dendreon. [Chief Executive Mitch] Gold did announce that Dendreon would hold its analyst day on Sept. 24 and gave a very positive update on their manufacturing facilities build-out in New Jersey and new operations in Georgia and California. Did I miss something? I just don't understand the current investor sentiment that clearly appears to be negative. Your thoughts? Thanks and take good care."
I read the transcript of Dendreon's conference call but I didn't see anything unexpected or worrisome. I haven't read or heard anything subsequently about any new investor concerns popping up.
Dendreon said it was going to raise money after the Provenge data -- and it did just that.
Dendreon said it wanted to use some of the proceeds of that financing to build two or three new Provenge manufacturing plants. The company is doing just that. Dendreon said it planned to hold an investor/analyst meeting in the fall and that its Provenge re-submission to the FDA would be completed in the fourth quarter. As Ben noted, the Dendreon meeting is scheduled for Sept. 24 and the Provenge filing is on track.
Not a lot of surprises here.
If forced to speculate, perhaps someone out there is worried about Dendreon spending too much money, too soon, on new Provenge manufacturing plants prior to the prostate cancer vaccine's approval. OK, understood, but the investment could also be seen as a signal that the company is very bullish about Provenge's commercial potential. It's not like Dendreon needs to build two new plants, since Provenge's approval and launch isn't contingent at all on their construction.
And don't forget, Dendreon's New Jersey manufacturing plant isn't even built out to full capacity yet and won't be at Provenge's launch.
I tend not to worry too much about mid-August stock trading. More often than not, a dip like that taken by Dendreon this week is an opportunity, not a cause for alarm.
http://www.thestreet.com/story/10575223/3/dendreon-vion-and-allos-biotech-mailbag.html
Ben L. writes, "I don't know if you listened to the recent Dendreon(DNDN Quote) quarterly conference call, but what was shared has obviously caused some concern amongst the investment community. The stock has been dropping since the call even though I have not seen any analyst downgrades for Dendreon. [Chief Executive Mitch] Gold did announce that Dendreon would hold its analyst day on Sept. 24 and gave a very positive update on their manufacturing facilities build-out in New Jersey and new operations in Georgia and California. Did I miss something? I just don't understand the current investor sentiment that clearly appears to be negative. Your thoughts? Thanks and take good care."
I read the transcript of Dendreon's conference call but I didn't see anything unexpected or worrisome. I haven't read or heard anything subsequently about any new investor concerns popping up.
Dendreon said it was going to raise money after the Provenge data -- and it did just that.
Dendreon said it wanted to use some of the proceeds of that financing to build two or three new Provenge manufacturing plants. The company is doing just that. Dendreon said it planned to hold an investor/analyst meeting in the fall and that its Provenge re-submission to the FDA would be completed in the fourth quarter. As Ben noted, the Dendreon meeting is scheduled for Sept. 24 and the Provenge filing is on track.
Not a lot of surprises here.
If forced to speculate, perhaps someone out there is worried about Dendreon spending too much money, too soon, on new Provenge manufacturing plants prior to the prostate cancer vaccine's approval. OK, understood, but the investment could also be seen as a signal that the company is very bullish about Provenge's commercial potential. It's not like Dendreon needs to build two new plants, since Provenge's approval and launch isn't contingent at all on their construction.
And don't forget, Dendreon's New Jersey manufacturing plant isn't even built out to full capacity yet and won't be at Provenge's launch.
I tend not to worry too much about mid-August stock trading. More often than not, a dip like that taken by Dendreon this week is an opportunity, not a cause for alarm.
12/8 2009 12:12 1970 016649 lidt mere dndn:
http://www.cnbc.com/id/32376558/site/14081545?__source=yahoo%7Cheadline%7Cquote%7Ctext%7C&par=yahoo
For years the Dendreon [DNDN 23.10 -0.78 (-3.27%) ] saga was centered around the controversy over whether its prostate cancer treatment worked or not.
Well, now that we know the answer to that question the focus has turned to potential FDA approval of the therapeutic vaccine and the company's ability to make it and master the unique treatment process.
But investors are also anxiously waiting for news on Dendreon's quest for a corporate partner to market Provenge outside the U.S.
On the biotech company's earnings conference call this morning CEO Dr. Mitchell Gold said, "We are in active discussions." A couple of analysts tried to press him for more details, but he wouldn't budge. CFO Greg Schiffman added, though, "We have no need to access the capital markets ahead of positive news from the FDA." Some might interpret that to mean the nearly quarter-billion dollars the company recently raised is enough to carry it through and/or more cash could soon be coming in the form of a so-called upfront payment from a potential partner.
In a research note this afternoon, Merriman Curhan Ford analyst Joe Pantginis estimates that down payment could be close to a hundred million bucks. He handicaps the odds of an ex-U.S. partnership versus a total takeout at 70-30. Pantginis names three potential partners or acquirers: Sanofi-Aventis, Bristol-Myers Squibb and GlaxoSmithKline. But if I were to reach out to those companies I can tell you what they'd say: "We don't comment on market rumors, speculation or analyst commentary regarding M and A or any other type of deal."
Stocks In This Postdndn23.10-0.78-3.27%2,131,623bmy21.970.09+0.41%12,733,054gsk38.59-0.31-0.8%1,170,732sny32.50-0.21-0.64%616,038
So, ahead of the potential partnership or acquisition Pantginis is telling clients, "Time to get in (to the stock.)" He has a $50 price target on DNDN. But investors, who might have been hoping for a big announcement today, are selling the shares which are up more than 400 percent this year. MCF makes a market in DNDN.
Also on CNBC.com:
Exclusive: Novartis CEO Speaks Out About Arsonist Attack
Deal negotiations aside, Dendreon is also busy ramping up for the Provenge launch. And on the conference call Dr. Gold indicated the vaccine could almost sell itself. Apparently the company did some kind of survey or something and found that Provenge had 90 percent brand recognition among targeted physicians. 90 percent brand recognition for a product that isn't even formally before the FDA yet and may not be on the market for another year or so! "We're fortunate that this is a product that physicians are already well aware of," he said. To me, that speaks volumes about how closely people have been watching this biotech drama, which is right now between acts, unfold.
http://www.cnbc.com/id/32376558/site/14081545?__source=yahoo%7Cheadline%7Cquote%7Ctext%7C&par=yahoo
For years the Dendreon [DNDN 23.10 -0.78 (-3.27%) ] saga was centered around the controversy over whether its prostate cancer treatment worked or not.
Well, now that we know the answer to that question the focus has turned to potential FDA approval of the therapeutic vaccine and the company's ability to make it and master the unique treatment process.
But investors are also anxiously waiting for news on Dendreon's quest for a corporate partner to market Provenge outside the U.S.
On the biotech company's earnings conference call this morning CEO Dr. Mitchell Gold said, "We are in active discussions." A couple of analysts tried to press him for more details, but he wouldn't budge. CFO Greg Schiffman added, though, "We have no need to access the capital markets ahead of positive news from the FDA." Some might interpret that to mean the nearly quarter-billion dollars the company recently raised is enough to carry it through and/or more cash could soon be coming in the form of a so-called upfront payment from a potential partner.
In a research note this afternoon, Merriman Curhan Ford analyst Joe Pantginis estimates that down payment could be close to a hundred million bucks. He handicaps the odds of an ex-U.S. partnership versus a total takeout at 70-30. Pantginis names three potential partners or acquirers: Sanofi-Aventis, Bristol-Myers Squibb and GlaxoSmithKline. But if I were to reach out to those companies I can tell you what they'd say: "We don't comment on market rumors, speculation or analyst commentary regarding M and A or any other type of deal."
Stocks In This Postdndn23.10-0.78-3.27%2,131,623bmy21.970.09+0.41%12,733,054gsk38.59-0.31-0.8%1,170,732sny32.50-0.21-0.64%616,038
So, ahead of the potential partnership or acquisition Pantginis is telling clients, "Time to get in (to the stock.)" He has a $50 price target on DNDN. But investors, who might have been hoping for a big announcement today, are selling the shares which are up more than 400 percent this year. MCF makes a market in DNDN.
Also on CNBC.com:
Exclusive: Novartis CEO Speaks Out About Arsonist Attack
Deal negotiations aside, Dendreon is also busy ramping up for the Provenge launch. And on the conference call Dr. Gold indicated the vaccine could almost sell itself. Apparently the company did some kind of survey or something and found that Provenge had 90 percent brand recognition among targeted physicians. 90 percent brand recognition for a product that isn't even formally before the FDA yet and may not be on the market for another year or so! "We're fortunate that this is a product that physicians are already well aware of," he said. To me, that speaks volumes about how closely people have been watching this biotech drama, which is right now between acts, unfold.
